Newsroom

Portrait of Thomas Pietschmann, TWINCORE
Interview
About 70 million people worldwide are chronically infected with the hepatitis C virus (HCV). Possible consequences include hepatitis, cirrhosis and liver cancer, but the disease often remains undetected for long periods of time. Thomas Pietschmann of the TWINCORE in Hannover investigates the virus and works on the development of a vaccine that could prevent HCV infections in the future.
01.05.2019
Portrait of Alice McHardy
Portrait
Alice McHardy reveals how she came to bioinformatics and what fascinates her about her work with massive volumes of data.
01.05.2019
Upper arm vaccination
Story
Carlos A. Guzmán's research team applies knowledge about the human immune system and its challengers to develop innovative vaccination strategies.
01.05.2019
Stereomicroscopic image of Cystobacter violaceus in red.
Story
Among all the hospital germs, Gram-negative bacteria are particularly difficult to treat: Many antibiotics fail due to the double-cell membrane. But cystobactamides are providing hope for a remedy – substances from the extensive collection of bacteria held by the HZI. These bacteria are going to be further developed into drugs in a partnership with the pharmaceutical company Evotec.
01.05.2019
Infact illustration of hepesvirus in blue
Story
Herpesviruses use sneaky tricks to permanently establish themselves in our cells and to spread efficiently in the population.
01.05.2019
Logo
News
The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), and the University of Queensland’s (UQ) Community for Open Antimicrobial Drug Discovery (CO-ADD) in its efforts to develop and ensure new antibiotics are globally available to all patients who need them. The agreement allows GARDP to access and test Calibr’s ReFRAME compound library and HIPS natural products library. Both libraries will be screened by CO-ADD to discover novel compounds or combinations of drugs that will kill the priority pathogens identified by the WHO in critical need for research and development of new antibiotics.
11.04.2019

HZI in the media

... der Fachzeitschrift Angewandte Chemie. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

15.05.2025
|
Verband Deutscher Biologen e.V.

including the University of Vienna and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), have turned to the study of

14.05.2025
|
Phys.org

darunter die Universität Wien und das Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS), sich der Erforschung von

14.05.2025
|
Science.apa.at

Josef Penninger, derzeit wissenschaftlicher Geschäftsführer des Helmholtz Zentrums für Infektionsforschung in Braunschweig, in Nature, dass ...

13.05.2025
|
LaborPraxis

... außerhalb des Magen-Darm-Traktes zu überleben. Das Helmholtz Zentrum für Infektionsforschung (HZI) bezeichnet die Clostridien als „ ...

12.05.2025
|
Frankfurter Rundschau online

Maximilians-Universität (JMU) Würzburg und des Würzburger Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) haben 2020 eine ...

11.05.2025
|
Medizin Aspekte